While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

When we take the time to be present and curious, we allow for more complex aesthetic and emotional responses to emerge.

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent ...

Illumina has introduced a new dataset to speed up drug discovery using artificial intelligence. This initiative involves ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Abstract: Engineers have developed abstract network models to better understand the recurring problems faced by communication systems. This paper argues that these models can be generalized to ...